Evidence that multiple myeloma may be regulated by homeostatic Summary Myeloma colonies (MY-CFUc) could be grown in vitro for 6 months (median time) after a group of 12 myeloma patients had reached complete remission (CR) . In a second group of 25 patients MY-CFU, increased in 17/25 and GM-CFUc in 20/25 patients after cyclophosphamide even though 24/25 patients had a partial response to VAMP and one was in CR. These data suggest that cell killing by cyclophosphamide stimulates residual tumour cells into proliferation and adds further support to the idea that myeloma is under some degree of homeostatic control which may be analogous to that in normal bone marrow. Although lymphoplasmacytoid myeloma cells may be more drug resistant than plasmacytoid myeloma cells in vitro, it was not possible to conclude that the emergence of lymphoplasmacytoid cells at relapse was indicative of resistance to further treatment.
In previously untreated multiple myeloma patients the complete remission rate to VAMP (vincristine, adriamycin and methyl prednisolone) is 6% (Gore et al., 1989) . This response rate is increased to 50% (Gore et al., 1989) following further treatment with high dose melphalan (HDM) with or without autologous bone marrow transplantation (ABMT), compared with 27% in patients who have received HDM as their only treatment (Selby et al., 1987) . For these purposes CR is defined as no measurable myeloma proteins on scanning densitometry of serum proteins separated on cellulose acetate membrane by electrophoresis and stained with Ponceau S; no detectable Bence Jones proteinuria on electrophoresis of neat urine stained with colloidal gold; and less than 5% plasma cells of normal morphology on bone marrow aspiration.
We have previously shown that two types of myeloma cell form colonies in vitro: cells which are large and plasmacytoid and those which are smaller and lymphoplasmacytoid . Drug sensitivity tests in vitro suggest that lymphoplasmacytoid myeloma cells are more resistant to adriamycin than plasmacytoid myeloma cells (Millar et al., 1989) . Furthermore, the clonogenicity of myeloma cells in vitro increases after VAMP despite a decrease in paraprotein and reduction in bone marrow infiltration with cells of plasma cell-like morphology suggesting that the reduction in tumour mass may stimulate quiescent cells into cycle or induce a more malignant phenotype to become dominant. Although multiple myeloma is characterised by malignant plasma cells it seems likely that the stem cell of the tumour is an earlier B cell and that major clonogenic expansion occurs in committed precursor cells which have undergone isotype specificity. The attainment of stable plateau phase in some patients despite measurable levels of paraprotein suggests that some degree of homeostatic regulation is present in multiple myeloma. Furthermore, the observation that at relapse multiple myeloma cells have more primitive morphology in patients who become refractory to treatment (Bartl et al., 1987) suggests that not all cells in the malignant clone have the same sensitivity to chemotherapeutic agents and in particular that more primitive cells may be more drug resistant. Thus, the removal of more mature and drug sensitive cells by chemotherapy may explain the emergence of these cells at relapse and why the duration of response tends to decrease at the second compared with first relapse (McElwain, 1987 (Millar et al., 1989 (MY-CFU,) and granulocyte-macrophage colonies (GM-CFU,) (Millar et al., 1989; Bradley et al., 1978) . Briefly, to culture MY-CFUc 5-10 x 105 MNC were added as an overlay in soft agar (0.2% final concentration) and alpha modification of Eagle's medium (containing 20% fetal bovine serum, 1% bovine serum albumin, 20 lg ml-' gentamycin sulphate) to an underlay consisting of 5 x 105 heavily irradiated HL60 cells in alpha medium and agar (0.5% final concentration) and incubated at 37'C for three weeks. Colonies (> 50 cells) were counted using an inverted microscope. Melphalan sensitivity was assessed using methods described (Millar et al., 1989) . These data were generated from survival curves for MY-CFUc and GM-CFUC following melphalan treatment made on the same bone marrow aspirates from each patient. Myeloma cells were designated resistant to melphalan if the ratio of the doses of melphalan required to reduce the surviving fraction to 10% between MY-CFU, and GM-CFU, was 4 or greater (Millar et al., 1989 Since all patients receive cyclophosphamide (400 mg m-2) 7 days before HDM to enhance the recovery of normal bone marrow progenitors (Millar et al., 1975) (Bonnet et al., 1982; Kyle et al., 1982) . Also, patients in CR have measurable disease using anti-idiotypic antibodies to detect the residual myeloma clone (Stevenson & Thompson, 1988) despite the restoration of normal haemopoiesis and absence of detectable paraprotein. Thus, although myeloma responds to treatment it must be thought of as a drugresistant tumour. The mechanism(s) of this resistance remains to be elucidated fully; however, our data show that drug resistance may be endogenous within the total myeloma cell population or result from changes in the population from cells which are drug-sensitive and resemble mature plasma cells to more primitive drug-resistant lymphoplasmacytoid cells (Millar et al., 1989) . In 12 patients who entered CR after VAMP/HDM, myeloma cells were measurable in vitro for approximately 6 months after patients entered CR. Four out of nine of their group of patients had myeloma cells that were resistant to melphalan in our clonogenic assay. Thus in vitro drug sensitivity per se is not a measure of whether patients will respond to treatment. The lag period between clinical and biological responses suggests that events other than drug-induced toxicity are involved in achieving a stable (non-proliferative) tumour cell population. It is arguable that the persistence of clonogenic cells at CR is analogous to the increase in clonogenicity reported previously after VAMP and after cyclophosphamide before patients receive HDM (see Table II ). In the original regime used by Barlogie dexamethasone was used in place of methyl prednisolone (VAD) and clinical remission was short in the absence of further treatment (Barlogie et al., 1984) . The enhanced log tumour cell kill by HDM compared to VAMP alone may reduce the number of clonogenic myeloma cells to a level at which they eventually fail to respond to autocrine or paracrine growth factors synthesised by the myeloma cell population or to paracrine factors synthesised by a second population of cells which is killed at the same time. Clearly some degree of homeostatic control exists in this tumour and that perturbation of the myeloma cell population (for example, killing of non-clonogenic cells) may result in the recruitment of dormant tumour cells .
Since MY-CFU, increased in 16/25 myeloma patients and GM-CFUC increased in 18/25 patients after treatment with cyclophosphamide even though 23/25 had a PR and 2/25 a CR (to VAMP), it is arguable that similar homeostatic control mechanisms exist in normal tissue as well as tumour. The concept that scheduling cytotoxic drugs in specific sequences may enhance the recovery of normal tissue has been established for more than a decade (Millar et al., 1975; Millar & McElwain, 1978) . In animal models this phenomenon has not been accompanied by sparing of tumour tissue (Evans et al., 1983 Since both plasmacytoid and lymphoplasmacytoid myeloma cells formed MY-CFU, in vitro from patients at first and second relapse, we cannot claim to predict the future response at second relapse of these patients to chemotherapy based on the emergence of lymphoplasmacytoid cells.
The present report emphasises that the growth of myeloma cells in vitro is dependent on the treatment that patients receive. Chemotherapy with VAMP and/or cyclophosphamide reproducibly increases the number of MY-CFU, in vitro even though patients have responded to treatment. This suggests that at presentation or relapse, when bone marrow infiltration may be high, a large proportion of the myeloma cell population are end cells or that colony growth in vitro is inhibited due to the high density of malignant cells, analogous to the inhibition of growth of cell lines in vitro when cells are seeded at concentrations approaching saturation density. Our method successfully mimicked the clinical response of patients who exhibited CR after VAMP/HDM although the mechanism of the clinical response cannot be explained entirely by the in vitro sensitivity of myeloma cells to melphalan.
